ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics" or the Company") (NYSE MKT: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license. The patent covers the treatment of brain cancer with a combination of a dendritic cell based vaccine combined either before or concurrently with the administration of chemotherapy. The Company believes that in the treatment of cancer, particularly cancers of the central nervous system such as glioblastoma multiforme (GBM), a dual therapeutic approach that includes the administration of a dendritic cell-based cancer vaccine combined with a regimen of chemotherapy could substantially enhance the clinical efficacy of treatment.    

"The strengthening of our world-wide intellectual property protection for the treatment and detection of cancers further supports our developmental efforts and enhances our ability to license or partner our immunotherapeutic platforms," said Manish Singh, Ph.D. President and CEO of ImmunoCellular Therapeutics. "It is with this in mind that we continue to pursue opportunities to solidify our intellectual property on a global scale."

Source: ImmunoCellular Therapeutics, Ltd.